Bio News
U.S.-based CellDex confirmed efficacy in two phase 3 trials of barzolizumab for the treatment of chronic spontaneous urticaria. In the barzolizumab groups, about half of patients had complete resolution of itching and hives after 24 weeks, compared with 15%-18% in the placebo groups.
CellDex reported two cases of anaphylaxis in one treatment group but said the incidence was very low among the more than 2,400 participants overall. The company plans to apply for U.S. Food and Drug Administration (FDA) approval next year.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
